S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   359.29 (+0.28%)
AAPL   172.99 (+1.04%)
MSFT   319.24 (+1.11%)
META   304.10 (+1.30%)
GOOGL   133.20 (+1.79%)
AMZN   128.87 (+1.38%)
TSLA   249.44 (-0.31%)
NVDA   445.89 (+2.51%)
NIO   8.75 (-3.21%)
BABA   86.17 (-0.66%)
AMD   102.31 (-0.50%)
T   14.69 (-2.20%)
F   12.26 (-1.29%)
MU   67.45 (-0.85%)
CGC   0.73 (-6.50%)
GE   108.59 (-1.77%)
DIS   81.29 (+0.30%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.42 (-0.07%)
NFLX   379.88 (+0.60%)
S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   359.29 (+0.28%)
AAPL   172.99 (+1.04%)
MSFT   319.24 (+1.11%)
META   304.10 (+1.30%)
GOOGL   133.20 (+1.79%)
AMZN   128.87 (+1.38%)
TSLA   249.44 (-0.31%)
NVDA   445.89 (+2.51%)
NIO   8.75 (-3.21%)
BABA   86.17 (-0.66%)
AMD   102.31 (-0.50%)
T   14.69 (-2.20%)
F   12.26 (-1.29%)
MU   67.45 (-0.85%)
CGC   0.73 (-6.50%)
GE   108.59 (-1.77%)
DIS   81.29 (+0.30%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.42 (-0.07%)
NFLX   379.88 (+0.60%)
S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   359.29 (+0.28%)
AAPL   172.99 (+1.04%)
MSFT   319.24 (+1.11%)
META   304.10 (+1.30%)
GOOGL   133.20 (+1.79%)
AMZN   128.87 (+1.38%)
TSLA   249.44 (-0.31%)
NVDA   445.89 (+2.51%)
NIO   8.75 (-3.21%)
BABA   86.17 (-0.66%)
AMD   102.31 (-0.50%)
T   14.69 (-2.20%)
F   12.26 (-1.29%)
MU   67.45 (-0.85%)
CGC   0.73 (-6.50%)
GE   108.59 (-1.77%)
DIS   81.29 (+0.30%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.42 (-0.07%)
NFLX   379.88 (+0.60%)
S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   359.29 (+0.28%)
AAPL   172.99 (+1.04%)
MSFT   319.24 (+1.11%)
META   304.10 (+1.30%)
GOOGL   133.20 (+1.79%)
AMZN   128.87 (+1.38%)
TSLA   249.44 (-0.31%)
NVDA   445.89 (+2.51%)
NIO   8.75 (-3.21%)
BABA   86.17 (-0.66%)
AMD   102.31 (-0.50%)
T   14.69 (-2.20%)
F   12.26 (-1.29%)
MU   67.45 (-0.85%)
CGC   0.73 (-6.50%)
GE   108.59 (-1.77%)
DIS   81.29 (+0.30%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.42 (-0.07%)
NFLX   379.88 (+0.60%)
NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News

$177.96
+0.86 (+0.49%)
(As of 02:28 PM ET)
Compare
Today's Range
$176.00
▼
$179.30
50-Day Range
$170.77
▼
$211.65
52-Week Range
$168.65
▼
$242.97
Volume
352,489 shs
Average Volume
679,881 shs
Market Capitalization
$22.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$245.52
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
37.8% Upside
$245.52 Price Target
Short Interest
Healthy
4.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
1.15mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2.81 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.79) to ($3.66) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

80th out of 969 stocks

Pharmaceutical Preparations Industry

22nd out of 453 stocks

See Top Rated MarketRank™ Stocks Here

ALNY stock logo

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Price History

ALNY Stock News Headlines

September 25, 2023 | marketbeat.com
Argenx's 28% Surge & Promising Product Propel Investor Confidence (ALNY)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
September 7, 2023 | marketbeat.com
3 Stocks to Buy For the COVID Resurgence (ALNY)
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
October 2, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
October 2, 2023 | news.yahoo.com
US FDA approves Novo Nordisk's therapy for rare genetic condition
September 30, 2023 | americanbankingnews.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Coverage Initiated at Raymond James
September 29, 2023 | msn.com
Raymond James Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Outperform Recommendation
September 26, 2023 | markets.businessinsider.com
Positive Clinical Trial Updates Boost Inozyme Pharma’s Buy Rating: Efficacy of INZ-701 in ENNP1 and ABCC6 Deficiencies
September 15, 2023 | msn.com
Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease
October 2, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
September 15, 2023 | msn.com
Alnylam stock falls after FDA panel questions drug's effectiveness
September 14, 2023 | msn.com
Alnylam’s RNA interference drug wins favour of FDA AdCom
September 14, 2023 | markets.businessinsider.com
Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects
September 13, 2023 | marketwatch.com
Alnylam Pharmaceuticals Says FDA Panel Votes in Favor of Onpattro's sNDA
September 13, 2023 | markets.businessinsider.com
Alnylam Pharmaceuticals: FDA Committee To Review SNDA For Patisiran; Trading Halted
September 12, 2023 | markets.businessinsider.com
What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
September 12, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and ADC Therapeutics (ADCT)
September 11, 2023 | benzinga.com
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
September 11, 2023 | bloomberg.com
FDA Casts Doubt on Alnylam Drug Trial Results for Expanded Usage
September 9, 2023 | seekingalpha.com
Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility
September 9, 2023 | reuters.com
Alnylam's gene-silencing drug cuts blood pressure in mid-stage trial
September 8, 2023 | bizjournals.com
BBJ honors corporate philanthropy leaders at annual event
September 8, 2023 | finance.yahoo.com
Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More
September 8, 2023 | markets.businessinsider.com
Citi Remains a Buy on Ionis Pharmaceuticals (IONS)
September 7, 2023 | bizjournals.com
Alnylam supports Cambridge-area addiction recovery program
September 7, 2023 | news.yahoo.com
Alnylam hypertension drug meets main goal in mid-stage study
September 7, 2023 | markets.businessinsider.com
Alnylam: KARDIA-1 Phase 2 Dose-Ranging Study Of Zilebesiran Meets Primary Endpoint
September 7, 2023 | finance.yahoo.com
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
CIK
1178670
Web
www.alnylam.com
Phone
(617) 551-8200
Fax
617-551-8101
Employees
2,002
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$245.52
High Stock Price Forecast
$405.00
Low Stock Price Forecast
$143.00
Forecasted Upside/Downside
+38.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
22 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($8.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,131,160,000.00
Net Margins
-85.95%
Pretax Margin
-85.63%
Return on Equity
-1,287.80%
Return on Assets
-30.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.20
Quick Ratio
3.07

Sales & Book Value

Annual Sales
$1.04 billion
Price / Sales
21.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.29) per share
Price / Book
-137.29

Miscellaneous

Outstanding Shares
125,000,000
Free Float
123,251,000
Market Cap
$22.14 billion
Optionable
Optionable
Beta
0.45

Social Links

12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Yvonne L. Greenstreet M.B.A. (Age 60)
    MBA, MBChB, CEO & Director
    Comp: $2.09M
  • Dr. Akshay K. Vaishnaw M.D. (Age 60)
    Ph.D., Pres
    Comp: $1.24M
  • Mr. Jeffrey V. Poulton M.B.A.Mr. Jeffrey V. Poulton M.B.A. (Age 55)
    CFO & Exec. VP
    Comp: $972.35k
  • Ms. Indrani M. Lall Franchini J.D.Ms. Indrani M. Lall Franchini J.D. (Age 51)
    Exec. VP, Chief Legal Officer & Sec.
    Comp: $958.96k
  • Dr. Pushkal P. Garg M.D. (Age 55)
    Chief Medical Officer and Exec. VP of Devel. & Medical Affairs
    Comp: $1M
  • Mr. Timothy J. Maines
    Chief Technical Operations & Quality Officer
  • Dr. Kevin Joseph Fitzgerald Ph.D. (Age 54)
    Sr. VP, Head of Research & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom (Age 42)
    Sr. VP of Investor Relations & Corp. Communications
  • Mr. Piyush Sharma J.D.
    Chief Ethics & Compliance Officer
  • Mr. Mark Baglin
    VP of Global Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 5 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price forecast for 2023?

22 Wall Street research analysts have issued 1 year target prices for Alnylam Pharmaceuticals' shares. Their ALNY share price forecasts range from $143.00 to $405.00. On average, they predict the company's stock price to reach $245.52 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2023?

Alnylam Pharmaceuticals' stock was trading at $237.65 at the start of the year. Since then, ALNY stock has decreased by 25.5% and is now trading at $177.10.
View the best growth stocks for 2023 here.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our ALNY earnings forecast.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($2.21) EPS for the quarter, missing analysts' consensus estimates of ($1.72) by $0.49. The biopharmaceutical company had revenue of $318.75 million for the quarter, compared to the consensus estimate of $331.73 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 1,287.80% and a negative net margin of 85.95%.

What ETFs hold Alnylam Pharmaceuticals' stock?

ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH) and Principal Healthcare Innovators ETF (BTEC).

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.46 billion, compared to the consensus revenue estimate of $1.44 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $177.10.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $22.14 billion and generates $1.04 billion in revenue each year. The biopharmaceutical company earns $-1,131,160,000.00 in net income (profit) each year or ($8.61) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

The company employs 2,002 workers across the globe.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -